Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer

Feng, Wei; Cui, Ge; Tang, Chengwu; Zhang, Xiaolan; Dai, Chuang; Xu, Yong; Gong, Hui; Xue, Ting; Guo, Huihui; Bao, Ying

doi:10.18632/oncotarget.18090

Cited by 40 publications

(51 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…56 GLUT is a family of glucose transporters, and has been extensively studied in cancer cells. As a glucose family, GLUT1 is the predominant transporter usually overexpressed in tumors, including hepatic, 57 lung, 58 colorectal, 59 and breast cancer. 60 The reduction of the expression levels of HIF1α and GLUT1 by EGCG, may represent a mechanism to explain the decrease in glucose consumption following EGCG treatment.…”

Section: Food and Function Papermentioning

confidence: 99%

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Food and Function Papermentioning

confidence: 99%

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC), one of the common malignancies in the human digestive system, ranks third in males and second in females worldwide (Feng et al, 2017). Surveillance and Health Services Research from the American Cancer Society estimates that 147,950 new CRC patients including of 78,300 males and 69,650 females will be diagnosed, and 28,630 men and 24,570 women will die of CRC in 2020 (Siegel et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

Chen

Wang

Lin

et al. 2020

Cell Biology International

View full text Add to dashboard Cite

This work aimed to investigate miR-93-5p expression in tumor tissue and its in vitro effects in colorectal cancer (CRC) by targeting programmed death ligand-1 (PD-L1). MiR-93-5p and PD-L1 expression was detected in CRC and adjacent normal tissues by quantitative real-time polymerase chain reaction and immunohistochemistry. The correlation between miR-93-5p and PD-L1 was validated by a dual-luciferase reporter assay. HCT116 and SW480 cells were divided into blank, miR-NC, miR-93-5p mimics, miR-93-5p inhibitor, PD-L1 small interfering RNA (siRNA) and miR-93-5p inhibitor + PD-L1 siRNA groups, and wound-healing and transwell assays were performed to detect cell migration and invasion, respectively. Protein expression was measured by western blotting. The secretion of cytokines was detected in the CRC cell/T coculture models. MiR-93-5p was downregulated in CRC tissues with upregulated PD-L1. In PD-L1-negative patients, miR-93-5p expression was increased compared with that in PD-L1-positive patients. MiR-93-5p and PD-L1 expression levels were associated with the tumor differentiation, lymphatic metastasis, TNM, Duke's stage, and prognosis of CRC. PD-L1 siRNA weakened the migration and invasion abilities via decreased expression of matrix metalloproteinase-1 (MMP-1), -2, and -9, and these effects were abolished by the miR-93-5p inhibitor. Additionally, anti-PD-L1 upregulated the expressions of interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), and interferon γ (IFN-γ) in the coculture of T cells with CRC cells, but downregulated the expressions of IL-1β, IL-10, and TGF-β. However, these changes were partially reversed by miR-93-5p inhibition. miR-93-5p is expected to be a novel target for CRC treatment since it decreases the migration and invasion, as well as the immune evasion, of CRC cells via targeting PD-L1. Abbreviations: CRC, colorectal cancer; ELISA, enzyme-linked immunosorbent assay; HE, hematoxylin and eosin; ITIM, immunoreceptor tyrosinebased inhibitory motif; miRNA, microRNA; PD-L1, programmed death ligand-1 Role of miR-93-5p in CRC via targeting PD-L1Y.-L. Chen et al.

show abstract

“…These SNPs have been studied in breast cancer cells through the measurement of fluorescently tagged glucose molecules 18F-FDG; however, there was no association between glucose uptake and these genotypes ( 45 ). However, the rs710218 SLC2A1-AS1 SNP has recently been shown to be associated with increased Glut1 expression in colorectal cancer tissue when at least one copy of the T allele was present in comparison to those with homozygous AA genotypes among individuals with colorectal cancer ( 71 ). These results do not correspond with our own, as we found non-favorable progression among the HIV-positive treatment-naive and elevated CD4+Glut1+ T cell percentage in HIV+/cART individuals to be associated with the rs710218 dominant A allele ( 71 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, the rs710218 SLC2A1-AS1 SNP has recently been shown to be associated with increased Glut1 expression in colorectal cancer tissue when at least one copy of the T allele was present in comparison to those with homozygous AA genotypes among individuals with colorectal cancer ( 71 ). These results do not correspond with our own, as we found non-favorable progression among the HIV-positive treatment-naive and elevated CD4+Glut1+ T cell percentage in HIV+/cART individuals to be associated with the rs710218 dominant A allele ( 71 ). Furthermore, other studies have shown that this SNP does not influence 18F-FDG uptake in breast cancer ( 72 ), suggesting that regulation of Glut1 expression by SNPs may be cell and context specific.…”

Section: Discussionmentioning

confidence: 99%

Polymorphism rs1385129 Within Glut1 Gene SLC2A1 Is Linked to Poor CD4+ T Cell Recovery in Antiretroviral-Treated HIV+ Individuals

et al. 2018

View full text Add to dashboard Cite

Untreated HIV infection is associated with progressive CD4+ T cell depletion, which is generally recovered with combination antiretroviral therapy (cART). However, a significant proportion of cART-treated individuals have poor CD4+ T cell reconstitution. We investigated associations between HIV disease progression and CD4+ T cell glucose transporter-1 (Glut1) expression. We also investigated the association between these variables and specific single nucleotide polymorphisms (SNPs) within the Glut1 regulatory gene AKT (rs1130214, rs2494732, rs1130233, and rs3730358) and in the Glut1-expressing gene SLC2A1 (rs1385129 and rs841853) and antisense RNA 1 region SLC2A1-AS1 (rs710218). High CD4+Glut1+ T cell percentage is associated with rapid CD4+ T cell decline in HIV-positive treatment-naïve individuals and poor T cell recovery in HIV-positive individuals on cART. Evidence suggests that poor CD4+ T cell recovery in treated HIV-positive individuals is linked to the homozygous genotype (GG) associated with SLC2A1 SNP rs1385129 when compared to those with a recessive allele (GA/AA) (odds ratio = 4.67; P = 0.04). Furthermore, poor response to therapy is less likely among Australian participants when compared against American participants (odds ratio: 0.12; P = 0.01) despite there being no difference in prevalence of a specific genotype for any of the SNPs analyzed between nationalities. Finally, CD4+Glut1+ T cell percentage is elevated among those with a homozygous dominant genotype for SNPs rs1385129 (GG) and rs710218 (AA) when compared to those with a recessive allele (GA/AA and AT/TT respectively) (P < 0.04). The heterozygous genotype associated with AKT SNP 1130214 (GT) had a higher CD4+Glut1+ T cell percentage when compared to the dominant homozygous genotype (GG) (P = 0.0068). The frequency of circulating CD4+Glut1+ T cells and the rs1385129 SLC2A1 SNP may predict the rate of HIV disease progression and CD4+ T cell recovery in untreated and treated infection, respectively.

show abstract

Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer

Cited by 40 publications

References 40 publications

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer

Polymorphism rs1385129 Within Glut1 Gene SLC2A1 Is Linked to Poor CD4+ T Cell Recovery in Antiretroviral-Treated HIV+ Individuals

Contact Info

Product

Resources

About